Could the next “blockbuster” drug be a combination of existing therapies? The Food & Drug Administration seems to think so.
The federal watchdog agency issued draft guidelines yesterday intended to encourage pharmaceutical companies to develop therapies from drug combinations.
The agency feels that despite the increased risk involved in combining pharmaceutical treatments, there are benefits to treating serious diseases such as cancer.